FLAURA2 trial

Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
ESMO 2023

Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial

Anika Sharma

ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...

IASLC WCLC 2023 Conference - Tagrisso, a targeted therapy, combined with chemotherapy, extended the median progression-free survival by nearly 9 months in patients with EGFR-mutated advanced lung cancer, according to the FLAURA2 Phase III trial.
Conferences Pharma

Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)

Anika Sharma

Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

© 2024 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us